OTCMKTS:AOBI

American Oriental Bioengineering Competitors

$1.28
0.00 (0.00 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.28
$1.28
50-Day Range
$1.20
$3.88
52-Week Range
$0.01
$5.00
Volume1 shs
Average Volume192 shs
Market Capitalization$93,440.00
P/E RatioN/A
Dividend YieldN/A
Beta-14.13

Competitors

American Oriental Bioengineering (OTCMKTS:AOBI) Vs. STLT, TRPXD, PFSCF, SKVI, EPRSQ, and ROSGQ

Should you be buying AOBI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to American Oriental Bioengineering, including Spotlight Innovation (STLT), Therapix Biosciences (TRPXD), ProMetic Life Sciences (PFSCF), Skinvisible (SKVI), EPIRUS Biopharmaceuticals (EPRSQ), and Rosetta Genomics (ROSGQ).

Spotlight Innovation (OTCMKTS:STLT) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Earnings and Valuation

This table compares Spotlight Innovation and American Oriental Bioengineering's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spotlight InnovationN/AN/AN/AN/AN/A
American Oriental BioengineeringN/AN/AN/AN/AN/A

Risk & Volatility

Spotlight Innovation has a beta of -105.24, indicating that its stock price is 10,624% less volatile than the S&P 500. Comparatively, American Oriental Bioengineering has a beta of -14.13, indicating that its stock price is 1,513% less volatile than the S&P 500.

Profitability

This table compares Spotlight Innovation and American Oriental Bioengineering's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spotlight InnovationN/AN/AN/A
American Oriental BioengineeringN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Spotlight Innovation and American Oriental Bioengineering, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spotlight Innovation0000N/A
American Oriental Bioengineering0000N/A

Summary

American Oriental Bioengineering beats Spotlight Innovation on 1 of the 1 factors compared between the two stocks.

Therapix Biosciences (OTCMKTS:TRPXD) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Therapix Biosciences and American Oriental Bioengineering's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Therapix BiosciencesN/AN/A$-4,790,000.00N/AN/A
American Oriental BioengineeringN/AN/AN/AN/AN/A

Profitability

This table compares Therapix Biosciences and American Oriental Bioengineering's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Therapix BiosciencesN/AN/AN/A
American Oriental BioengineeringN/AN/AN/A

Insider and Institutional Ownership

14.3% of Therapix Biosciences shares are owned by institutional investors. 30.3% of American Oriental Bioengineering shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Therapix Biosciences and American Oriental Bioengineering, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Therapix Biosciences0000N/A
American Oriental Bioengineering0000N/A

ProMetic Life Sciences (OTCMKTS:PFSCF) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares ProMetic Life Sciences and American Oriental Bioengineering's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life Sciences-894.02%-3,350.55%-67.76%
American Oriental BioengineeringN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for ProMetic Life Sciences and American Oriental Bioengineering, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
American Oriental Bioengineering0000N/A

Earnings and Valuation

This table compares ProMetic Life Sciences and American Oriental Bioengineering's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life Sciences$36.55 million3.49$-150,730,000.00N/AN/A
American Oriental BioengineeringN/AN/AN/AN/AN/A

American Oriental Bioengineering has lower revenue, but higher earnings than ProMetic Life Sciences.

Institutional & Insider Ownership

0.1% of ProMetic Life Sciences shares are held by institutional investors. 30.3% of American Oriental Bioengineering shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

ProMetic Life Sciences has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500. Comparatively, American Oriental Bioengineering has a beta of -14.13, suggesting that its stock price is 1,513% less volatile than the S&P 500.

Summary

American Oriental Bioengineering beats ProMetic Life Sciences on 4 of the 7 factors compared between the two stocks.

Skinvisible (OTCMKTS:SKVI) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Skinvisible and American Oriental Bioengineering, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Skinvisible0000N/A
American Oriental Bioengineering0000N/A

Profitability

This table compares Skinvisible and American Oriental Bioengineering's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Skinvisible-1,027.05%N/A-834.18%
American Oriental BioengineeringN/AN/AN/A

Volatility & Risk

Skinvisible has a beta of -0.44, meaning that its share price is 144% less volatile than the S&P 500. Comparatively, American Oriental Bioengineering has a beta of -14.13, meaning that its share price is 1,513% less volatile than the S&P 500.

Valuation & Earnings

This table compares Skinvisible and American Oriental Bioengineering's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Skinvisible$40,000.007.38$-1,700,000.00N/AN/A
American Oriental BioengineeringN/AN/AN/AN/AN/A

American Oriental Bioengineering has lower revenue, but higher earnings than Skinvisible.

EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and American Oriental Bioengineering (OTCMKTS:AOBI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Risk and Volatility

EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its share price is 503% more volatile than the S&P 500. Comparatively, American Oriental Bioengineering has a beta of -14.13, suggesting that its share price is 1,513% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for EPIRUS Biopharmaceuticals and American Oriental Bioengineering, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
EPIRUS Biopharmaceuticals0000N/A
American Oriental Bioengineering0000N/A

Profitability

This table compares EPIRUS Biopharmaceuticals and American Oriental Bioengineering's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EPIRUS BiopharmaceuticalsN/AN/AN/A
American Oriental BioengineeringN/AN/AN/A

Earnings and Valuation

This table compares EPIRUS Biopharmaceuticals and American Oriental Bioengineering's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EPIRUS BiopharmaceuticalsN/AN/AN/AN/AN/A
American Oriental BioengineeringN/AN/AN/AN/AN/A

Summary

EPIRUS Biopharmaceuticals beats American Oriental Bioengineering on 1 of the 1 factors compared between the two stocks.

American Oriental Bioengineering (OTCMKTS:AOBI) and Rosetta Genomics (OTCMKTS:ROSGQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Earnings and Valuation

This table compares American Oriental Bioengineering and Rosetta Genomics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Oriental BioengineeringN/AN/AN/AN/AN/A
Rosetta GenomicsN/AN/AN/AN/AN/A

Profitability

This table compares American Oriental Bioengineering and Rosetta Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Oriental BioengineeringN/AN/AN/A
Rosetta GenomicsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for American Oriental Bioengineering and Rosetta Genomics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Oriental Bioengineering0000N/A
Rosetta Genomics0000N/A

Risk and Volatility

American Oriental Bioengineering has a beta of -14.13, indicating that its stock price is 1,513% less volatile than the S&P 500. Comparatively, Rosetta Genomics has a beta of 6.39, indicating that its stock price is 539% more volatile than the S&P 500.

Summary

Rosetta Genomics beats American Oriental Bioengineering on 1 of the 1 factors compared between the two stocks.


American Oriental Bioengineering Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01flat$343,000.00N/A0.00
TRPXD
Therapix Biosciences
0.0$6.78flat$339,000.00N/A0.00High Trading Volume
Gap Up
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00News Coverage
Gap Down
SKVI
Skinvisible
0.7$0.07flat$295,000.00$40,000.000.00High Trading Volume
Gap Down
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01flat$195,000.00N/A0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.09flat$164,000.00N/A0.00Gap Up
WDBG
Woodbrook Group
0.0$1.11flat$155,000.00N/A0.00Gap Down
PZRXQ
PhaseRx
0.2$0.01flat$147,000.00N/A0.00High Trading Volume
Gap Up
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.01flat$83,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.01flat$6,000.00$110,000.000.00Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.08flat$0.00N/A0.00Gap Down
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.02flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$33.79flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.84flat$0.00$263.61 million0.00Gap Down
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.06flat$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06flat$0.00$26.09 million0.00
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Down
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.